# Trade Mark Journal No.2026/002 9 January 2026

## WO0000001892606 (5,42)

Office of origin: United States of America

Date of International Registration:17 November 2025
Date of designation in the UK: 17 November 2025

International priority date claimed: 12 June 2025 (United States of America) (99231433)

Class 5
  Pharmaceutical preparations and substances for the treatment of autoimmune diseases and disorders, viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, ophthalmic, respiratory, neurological, neuromuscular, gastrointestinal, hormonal, dermatological, psychiatric, and immune system related diseases and disorders.
Class 42
  Research and development in the pharmaceutical and biotechnology fields; providing medical research information in the field of pharmaceuticals; providing scientific research information in the field of pharmaceuticals.

Biohaven Therapeutics Ltd.

Representative: Monica Riva Talley Sterne, Kessler, Goldstein & Fox P.L.L.C., 1101 K Street, N.W.,, 10th Floor, Washington DC 20005, UNITED STATES OF AMERICA